Optiver Holding
LRMR icon

Optiver Holding’s Larimar Therapeutics LRMR Stock Holding History

Optiver Holding’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.47K Buy
+2,449
New +$9.72K ﹤0.01% 1827
2025
Q4 		– Sell
-560
Closed -$1.81K – 2758
2025
Q3 		$1.81K Buy
+560
New +$2.1K ﹤0.01% 2415

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Optiver Holding's LRMR Position: Q2 2026 in Review

Optiver Holding opened a new position in Larimar Therapeutics (LRMR) in Q2 2026: 2,449 shares worth $7.47K. The stake represents ﹤0.01% of the portfolio and ranks #1827 among its holdings. This is a return to the name: Optiver Holding previously reported a position in LRMR as recently as Q3 2025.

Optiver Holding first reported a position in LRMR in Q3 2025 and has held it in 2 quarters since. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Optiver Holding held 2,449 shares of Larimar Therapeutics worth $7.47K as of Q2 2026.
  • Larimar Therapeutics was a new Optiver Holding position in Q2 2026.
  • Larimar Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #1827 holding.
  • Optiver Holding first reported a position in Larimar Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.